Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Mylan Inc.’s (MYL - Analyst Report) generic segment was boosted when the company launched its generic version of Pfizer Inc.’s (PFE - Analyst Report) anti fungal drug Vfend (voriconazole). The product (oral suspension) was launched, following the final approval of Mylan’s abbreviated new drug application (ANDA) by the U.S. Food and Drug Administration (FDA), to market its generic version of Vfend.

Since Mylan was the first-to-file an ANDA for a generic version of Vfend, the company was granted 180 days of marketing exclusivity. As per IMS Health data, Vfend sales in the U.S. were $17.1 million for the twelve months ended Jun 30, 2013.

Mylan, one of the largest players in the global generics market, has a presence in more than 140 countries. As of Sep 30, 2013, the company had 178 ANDAs pending FDA approval, representing $83.8 billion in annual sales. These include 42 first-to-file opportunities, representing $23.8 billion in annual sales. The data released by IMS Health is for the twelve-month period ending Dec. 31, 2012.

Mylan’s generic unit is its main growth driver. Bulk of the revenues of the company is generated from generic third-party net sales, derived from sales in North America, Europe, the Middle East & Africa and Asia-Pacific. Moreover, Mylan has a strong generic pipeline and should continue benefiting from a large number of high-value branded drugs scheduled to go off patent in the next couple of years. These patent expirations should boost the generic product portfolio of Mylan.

Mylan carries a Zacks Rank #2 (Buy). Akorn, Inc. (AKRX - Snapshot Report) is another Zacks #2 Ranked stock in the generic space. Actavis, Inc. (ACT - Analyst Report), another generic player, looks more attractive with a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GROUP DXYN 15.84 +7.90%
BOFL HOLDING BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%